Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS

被引：0
|
作者：
Pawlikowska, P.
Kosmider, O. [1 ]
Park, S. [1 ]
Bardet, V. [1 ]
Kuhnowsky, F.
Pierre-Eugene, C.
Picard, F.
Viallon, V.
Viguie, F. [2 ]
Mayeux, P.
Lacombe, C. [1 ]
Porteu, F.
Dreyfus, F. [1 ]
Fontenay, M. [1 ]
机构：
[1] Univ Paris 05, Hop Cochin, APHP, INSERM,U567, Paris, France
[2] Univ Paris 05, Hotel Dieu, APHP, Paris, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70072-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [31] Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
    Goncalves, Ana Cristina
    Alves, Raquel
    Baldeiras, Ines
    Jorge, Joana
    Marques, Barbara
    Paiva, Artur
    Oliveiros, Barbara
    Cortesao, Emilia
    Costa, Jose Manuel Nascimento
    Sarmento-Ribeiro, Ana Bela
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [32] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Castelli, Roberto
    Schiavon, Riccardo
    Rossi, Valentina
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [33] Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes
    Cerchione, Claudio
    Alfinito, Fiorella
    Soriente, Ilaria
    D'Arco, Alfonso Maria
    Danise, Paolo
    Cerciello, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S325
  • [34] Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life
    Oliva, E.
    Latagliata, R.
    Breccia, M.
    Morabito, F.
    Ghio, R.
    Poloni, A.
    Barate, C.
    Cortelezzi, A.
    Ricco, A.
    Alati, C.
    Spiriti, M. Aloe
    Nobile, F.
    LEUKEMIA RESEARCH, 2009, 33 : S123 - S123
  • [35] CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS
    Kosmider, O.
    Passet, M.
    Santini, V.
    Platzbecker, U.
    Andrieu, V.
    Zini, G.
    Beyne-Rauzy, O.
    Guerci, A.
    Slama, B.
    Fenaux, P.
    Dreyfus, F.
    Fontenay, M.
    Park, S.
    LEUKEMIA RESEARCH, 2015, 39 : S56 - S56
  • [36] CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS
    Kosmider, O.
    Passet, M.
    Santini, V.
    Platzbecker, U.
    Andrieu, V.
    Zini, G.
    Beyne-Rauzy, O.
    Fenaux, P.
    Dreyfus, F.
    Fontenay, M.
    Park, S.
    HAEMATOLOGICA, 2015, 100 : 191 - 191
  • [37] Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study
    Panichi, Vincenzo
    Rosati, Alberto
    Bigazzi, Roberto
    Paoletti, Sabrina
    Mantuano, Emanuela
    Beati, Sara
    Marchetti, Valentina
    Bernabini, Giada
    Grazi, Giovanni
    Rizza, Giovanni Manca
    Migliori, Massimiliano
    Giusti, Riccardo
    Lippi, Alberto
    Casani, Aldo
    Barsotti, Giuliano
    Tetta, Ciro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (08) : 2641 - U1808
  • [38] Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
    A. A. van de Loosdrecht
    E. M. P. Cremers
    C. Alhan
    C. Duetz
    F. E. M. in ’t Hout
    H. A. Visser-Wisselaar
    D. A. Chitu
    A. Verbrugge
    S. M. Cunha
    G. J. Ossenkoppele
    J. J. W. M. Janssen
    S. K. Klein
    E. Vellenga
    G. A. Huls
    P. Muus
    S. M. C. Langemeijer
    G. E. de Greef
    P. A. W. te Boekhorst
    M. H. G. Raaijmakers
    M. van Marwijk Kooy
    M. C. Legdeur
    J. J. Wegman
    W. Deenik
    O. de Weerdt
    T. M. van Maanen-Lamme
    P. Jobse
    R. J. W. van Kampen
    A. Beeker
    P. W. Wijermans
    B. J. Biemond
    B. C. Tanis
    J. W. J. van Esser
    C. G. Schaar
    H. S. Noordzij-Nooteboom
    E. M. G. Jacobs
    A. O. de Graaf
    M. Jongen-Lavrencic
    M. J. P. L. Stevens-Kroef
    T. M. Westers
    J. H. Jansen
    Leukemia, 2024, 38 : 840 - 850
  • [39] Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
    van de Loosdrecht, A. A.
    Cremers, E. M. P.
    Alhan, C.
    Duetz, C.
    In 't Hout, F. E. M.
    Visser-Wisselaar, H. A.
    Chitu, D. A.
    Verbrugge, A.
    Cunha, S. M.
    Ossenkoppele, G. J.
    Janssen, J. J. W. M.
    Klein, S. K.
    Vellenga, E.
    Huls, G. A.
    Muus, P.
    Langemeijer, S. M. C.
    de Greef, G. E.
    te Boekhorst, P. A. W.
    Raaijmakers, M. H. G.
    van Marwijk Kooy, M.
    Legdeur, M. C.
    Wegman, J. J.
    Deenik, W.
    de Weerdt, O.
    van Maanen-Lamme, T. M.
    Jobse, P.
    van Kampen, R. J. W.
    Beeker, A.
    Wijermans, P. W.
    Biemond, B. J.
    Tanis, B. C.
    van Esser, J. W. J.
    Schaar, C. G.
    Noordzij-Nooteboom, H. S.
    Jacobs, E. M. G.
    de Graaf, A. O.
    Jongen-Lavrencic, M.
    Stevens-Kroef, M. J. P. L.
    Westers, T. M.
    Jansen, J. H.
    LEUKEMIA, 2024, 38 (04) : 840 - 850
  • [40] Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level
    Sanz Ortiz, Jaime
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (08): : 486 - 492
12345